From rapid injection to vulnerable MLOps to models that unknowingly memorize patient data, the attack surfaces introduced by AI in pharmaceutical research have gone beyond what traditional compliance frameworks were built to address.
Protecting sensitive information has become a major challenge for modern organizations, especially in high-tech fields such as drug development, where clinical trial datasets and patient health information are critical to innovation. Frameworks such as ISO 27001 again SOC 2and other recognized values, play an important role in building trust. They provide a strong and structured foundation for security systems, formal governance, access control, risk management, vendor monitoring, incident response and auditing. Achieving these certifications demonstrates true operational maturity and demonstrates an organization-wide commitment to data protection.
Yet for AI companies handling highly sensitive assets such as patient health records, biometrics and proprietary clinical trial datasets, security cannot stop at compliance, even if compliance is achieved at the highest level. AI systems introduce new attack surfaces and fast-moving threat models that require continuous improvement: model exploitation, data leakage in all training and assumed workflows, rapid injection and vulnerability in all complex machine operation pipelines (MLOps). In this situation, the question is no longer whether the organization meets the standard but can maintain trust under changing conditions.
That difference is now evident at the regulatory level. The EU AI legislation, which is now in force, introduces binding requirements for security and transparency high-risk AI systemsincluding those used in health care and life sciences. In the US, the FDA has been expanding its guidance Medical devices powered by AI and softwaremost recently for its application of AI in drug development. These frameworks are designed to replace the technical ISO and SOC certifications that preceded them. The gap between what compliance requires and what regulators are beginning to demand is real, and growing.
Nowhere is this change more urgent than in the increasing use of AI in pharmaceutical research and development. Drug discovery and clinical trials are increasingly empowered by machine learning models that can map biological interactions, accelerate patient recruitment and improve study design. As these systems develop, AI platforms are beginning to predict trial results and simulate potential treatments at speeds that would have been unimaginable a decade ago. The result is a profound acceleration of innovation, but also a dramatic increase in the sensitivity, value and scale of the data being processed.
Clinical trial datasets often contain highly personal health information and represent one of the most important creative assets in the life sciences industry. When AI systems are used to analyze and simulate these datasets, the stakes are raised. Security failures in this context are not just data breaches. It may reveal proprietary research, compromise patient privacy and may undermine the integrity of results before the clinical trial is completed. The health and life sciences industry has already learned this lesson at great cost. I 2024 Change Healthcare ransomware attackamong the most disruptive cyber incidents in US healthcare history, exposed sensitive patient data on an unprecedented scale and disrupted clinic and pharmacy operations across the country for weeks. It was a reminder that the consequences of security failures in this sector are operational, financial and deeply personal.
As pharmaceutical companies integrate AI more deeply into drug development and simulation platforms, an important question arises: are their safety measures advancing at the same pace as their technology? Too often, compliance frameworks are considered a static milestone rather than a dynamic system. An organization may receive ISO 27001 certification or pass a SOC 2 audit, but those milestones represent a point-in-time validation, not a guarantee of continued robustness.
This gap becomes especially obvious when AI systems are involved. Models may not be accurate memorize certain pieces of sensitive data they are trained there, something that has become central to discussions about privacy-preserving machine learning. In the context of a clinical trial, where training data may include identifiable patient records or aggregated proprietary data, risk is not abstract. A model that absorbs sensitive information during training can reproduce its own fragments under certain conditions, with results that are not conformance tests designed to identify or prevent. At the same time, the growing ecosystem of third-party tools, data pipelines and infrastructure used to develop and deploy AI presents additional points of vulnerability that compliance checklists were never designed to capture. Without continuous monitoring and strong defenses, organizations are at risk of building AI-powered systems on security foundations that were designed for a slower, less complex age of technology.
Building true cyber resilience requires a fundamental mindset shift. Instead of assuming that controls will prevent all breaches, organizations need to build systems with the assumption that compromises are possible and plan accordingly. This means isolating sensitive data sets, monitoring systems for abnormal behavior, stress-testing models and infrastructure before adversaries act and reacting quickly when incidents occur. It also requires embedding security thinking directly into product design, research workflows and executive decision-making. CISOs, CTOs and heads of research at pharmaceutical and biotech companies should start asking a new set of questions: not just whether their organization has passed the latest test, but whether their security posture is aligned with their AI capabilities.
This approach is consistent with where the policy is heading. The Cybersecurity and Infrastructure Security Agency (CISA) of the US has been promoting it principles that are protected by designonce 2023 National Security Strategy clearly called for shifting the responsibility for protection to technology producers rather than end users. The current administration’s approach to that framework continues to evolve, but the basic direction is clear: security is expected to be built in from the ground up.
Ultimately, the aim is not to diminish the importance of ISO or SOC frameworks. These standards remain important pillars of governance, accountability and operational excellence. But in an era where AI is revolutionizing drug development and clinical research, compliance alone cannot guarantee safety. Organizations leading the next phase of innovation will be those that treat certification not as a destination, but as a starting point for an evolving security strategy.
